Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

IDH1 mutation predicts response and survival in treatment-naïve Acute Myeloid Leukemia patients receiving with venetoclax with a hypomethylating agent

View Full Paper
Ask AI
Bookmark
Share

Authors

ABAyrton BangoloBABehzad Amoozgar

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows venetoclax improves overall survival in acute myeloid leukemia patients with idh1 mutations, highlighting the importance of genetic profiling.

Key Points

  • To evaluate the impact of genetic mutations, particularly IDH1, on treatment outcomes in ND-AML patients receiving Ven-HMA therapy.
  • Retrospective, single-center study of ND-AML patients
  • Included patients underwent next-generation sequencing and cytogenetic profiling
  • Patients received at least one cycle of HMA therapy combined with venetoclax
  • Key outcomes measured included CR/CRi and survival using regression models
  • 79% achieved composite complete remission (CR/CRi)
  • Median overall survival was 11.47 months
  • Presence of TP53 mutation associated with inferior response
  • Achieving CR/CRi and IDH1 mutation associated with superior overall survival

Cite This Study

Bangolo et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e27ehttps://doi.org/10.1182/blood-2025-7032
View Full Paper
Ask AI
Bookmark
Share